نتایج جستجو برای: sitagliptin phosphate

تعداد نتایج: 105931  

2012
Akira Kubota Hajime Maeda Akira Kanamori Kiyokazu Matoba Yasuyuki Jin Fuyuki Minagawa Mitsuo Obana Koutarou Iemitsu Shogo Ito Hikaru Amemiya Mizuki Kaneshiro Masahiko Takai Hideaki Kaneshige Kazuhiko Hoshino Masashi Ishikawa Nobuaki Minami Tetsuo Takuma Nobuo Sasai Sachio Aoyagi Takehiro Kawata Atsuko Mokubo Hiroshi Takeda Shin Honda Hideo Machimura Tetsuya Motomiya Manabu Waseda Yoshikazu Naka Yasushi Tanaka Yasuo Terauchi Ikuro Matsuba

BACKGROUND Sitagliptin is a DPP-4 inhibitor that became available for use in Japan three years ago. This study was conducted to identify the pleiotropic effects of sitagliptin other than blood glucose lowering in Japanese type 2 diabetes mellitus patients. METHODS A retrospective, observational study of 940 type 2 diabetes mellitus patients was conducted. The primary outcome measures were HbA...

Journal: :Endocrine journal 2010
Kazutaka Aoki Kiyomi Masuda Takashi Miyazaki Yu Togashi Yasuo Terauchi

alpha-glucosidase inhibitors (alphaGIs) increase active glucagon-like peptide-1 (GLP-1) and reduce the total glucosedependent insulinotropic polypeptide (GIP) levels, but their ability to prevent diabetes remains uncertain. Dipeptidyl peptidase-4 (DPP-4) inhibitors, such as sitagliptin, increase active GLP-1 and GIP levels and improve hyperglycemia in a glucose-dependent fashion. However, the e...

2015
Hyun Min Kim Jung Soo Lim Byung-Wan Lee Eun-Seok Kang Hyun Chul Lee Bong-Soo Cha

BACKGROUND Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch. METHODS Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia....

2013
Balaji Samikannu Chunguang Chen Neelam Lingwal Manju Padmasekar Felix B. Engel Thomas Linn

Substitution of pancreatic islets is a potential therapy to treat diabetes and it depends on reconstitution of islet's capillary network. In this study, we addressed the question whether stabilization of Glucagon-Like-Peptide-1 (GLP-1) by inhibiting Dipeptidyl Peptidase-IV (DPP-IV) increases β-cell mass by modulating vascularization. Mouse or porcine donor islets were implanted under kidney cap...

2015
Hae Kyung Yang Borami Kang Seung-Hwan Lee Hun-Sung Kim Kun-Ho Yoon Bong-Yun Cha Jae-Hyoung Cho

BACKGROUND This study aimed to evaluate the effect of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, on insulin secretion and glucagon suppression in Korean subjects with type 2 diabetes mellitus. METHODS Twenty-four subjects underwent a 75-g oral glucose tolerance test (OGTT) before and after 6 months of sitagliptin treatment. Sitagliptin, insulin, and sulfonylurea were withdrawn for...

Journal: :Endocrine journal 2013
Tomoyuki Katsuno Hiroki Ikeda Kenichi Ida Jun-Ichiro Miyagawa Mitsuyoshi Namba

The effect of add-on therapy with sitagliptin on glycemic control was prospectively investigated in patients with type 2 diabetes mellitus (T2DM) receiving insulin alone or insulin combined with oral antidiabetic drugs. Seventy-one patients were evaluated (38 men and 33 women aged 63.9 ± 10.2 years). They were divided into three groups, which were 45 patients receiving premixed insulin twice da...

2011
S Al Sifri A Basiounny A Echtay M Al Omari I Harman-Boehm G Kaddaha K Al Tayeb A S Mahfouz A Al Elq L Radican C Özesen H L Katzeff B J Musser S Suryawanshi C J Girman M J Davies S S Engel

AIMS To compare the incidence of symptomatic hypoglycaemia in fasting Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan. METHODS Patients with type 2 diabetes (age ≥ 18 years) who were treated with a stable dose of a sulphonylurea with or without metformin for at least 3 months prior to screening, who had an HbA(1c) < 10% and who expressed their i...

Journal: :The New England journal of medicine 2015
Jennifer B Green M Angelyn Bethel Paul W Armstrong John B Buse Samuel S Engel Jyotsna Garg Robert Josse Keith D Kaufman Joerg Koglin Scott Korn John M Lachin Darren K McGuire Michael J Pencina Eberhard Standl Peter P Stein Shailaja Suryawanshi Frans Van de Werf Eric D Peterson Rury R Holman

BACKGROUND Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy ...

2014
Chun-Jun Li Xiao-Juan Liu Lian Bai Qian Yu Qiu-Mei Zhang Pei Yu De-Min Yu

BACKGROUND The oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese type 2 diabetes patients. METHODS In this 24-week, randomized, open-label, parallel clinical trial...

Journal: :Arquivos brasileiros de endocrinologia e metabologia 2014
Joelma Ines Tagliapietra Barros Francisco Vagnaldo Fechine Renan Magalhães Montenegro Júnior Otoni Cardoso do Vale Virgínia Oliveira Fernandes Marcellus Henrique Loiola Ponte de Souza Gilmara Holanda da Cunha Manoel Odorico de Moraes Catarina Brasil d'Alva Maria Elisabete Amaral de Moraes

OBJECTIVE To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy. MATERIALS AND METHODS Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید